Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
At the risk of looking like a total idiot, what bearing does the OB stuff have on the current patent case?
And mercifully the day comes to a close!
Raf - you said they would be issuing something today.
Nothing from AMRN yet. You sure their gonna issue a “rebuttal”?
Is she aware of all the false reports circulating?
After today I wouldn’t be too sure about 20-21. May end up being 18 or 19 to 20
A rocket ship ready to go or a rocket ship with more to go
Yep, huge difference??
Good grief, a little anal there Miller?
Thx KG
I feel constantly confused over the litigation and probably keep posing the same questions. That said, how does Reduce It help our case with Marine?
So, trial is set for 1/13?
New blog out by Markman on the patent stuff. Focus on ReduceIt. Their take on the situation seems more negative (to me) on AMRN prevailing than their first blog
Thank you Hamoa!
Well, that’s your answer. Let’s hope it is also the judge’s answer. Have you even read the Markman article or HDG’s synopsis?
No Raf. It is about what was obvious (or not ) at Marine time. TG, LDL and apoB.
RAF - not for the current litigation. Forget Reduce It. It is not relevant (strange as that may sound)
Again, trial is not about CV reduction
Never mind, I found it
Which lawyer are you referring to?
I don't know guys/gals. Throughout the R-It trial I so oftened relied on the collective conscious and intelligence of this board to keep me in the game. Sure I did my own research, but it was guys like JL and others with far more understanding of the science that kept me invested.
After the stellar R-It results I was still nervous over the AdCom and label approval but, deep inside, I knew the results were irrefutable. We had approval in the bag.
Now this f*cking patent issue. This one drives me nuts as we are at the mercy of the subjective (albeit intelligent) reasoning of a judge. No certainties here. If things to south... well, I can't bear to think. While I haven't made the millions some of you have, this investment has positioned me to retire in the next five or so years provided we don't lose this one.
Don't mean to spread FUD. Just sharing how I feel. Anyone hedging the pending trial with Puts?
Hamoa - Thx for weighing in again today. When is the judge expected to rule on Reduce It?
Jas/Raf - I don't think it is about the CV benefit unless RIt is allowed into evidence. So, unless that happens, forget about the CV benefit. As of now, it's about TG, LDL-C, and Apo-B.
Dude - my bad, Hayashi did show Apo-B decrease. Are we screwed?
Thx Dude for reply. My take (but what do I know) is any mis-statements on TG levels is irrelevant given the Apo-B decrease as there was nothing obvious about that from prior studies
I thought the examiner finally approved patents due to Apo-B decreases
You as well
I sent a rebuttal as well. Probably too soft but here it is. No reply as yet.
David,
With all due respect, you need to educate yourself a little before writing about Vascepa. While Vascepa (icosapent ethyl) is derived from fish oil, it is no more fish oil than aspirin is tree bark or penicillin is mold. Regarding the cost of Vascepa, are you familiar with the economic assessment done by the Institute for Clinical and Economic Review (ICER)? Vascepa is extremely cost effective. Looking backwards, you may be correct about insurance coverage. However, Vascepa just received its FDA label for CV risk reduction. Insurance coverage will follow (already is).
Not meaning to rag on you, but this is the single biggest breakthrough in cardiovascular space since statins. Nothing else has even come close. Without question, Vascepa is the number 1 finding of 2019.
Have a happy new year,
Tim
HDG - Thx so much. I think I'm starting to get it.
One more question if I could. In what way does/did AMRN's "Marine" label encourage physicians to prescribe longer than 12 weeks? (As I understand things, the label itself makes no reference to treatment duration).
HDG - I'm trying my best to keep up with all you intelligent folks. So, Reddy is essentially going after the Marine label? If correct and they prevail, won't Docs keep prescribing the generic beyond 12 weeks if the patient meets the RIt profile (assuming the generic is cheaper).
Is this the crux of the infringement argument by AMRN? Is AMRN allowed to bring RIt into the picture?
Thx STS
HDG
Thx for your excellent summary. I’m confused by your following paragraph.
(b) We do not have all documents, do not know all arguments … but we know - re. the Hayashi study – that the examiner accepted as true Dr. Lavin’s opinion that the prior art did not teach administering purified EPA to patients with triglycerides of at least 500 mg/dL, which the parties now agree was incorrect, Defendants only seek to show that the asserted patents were issued based on factual mistakes about the prior art
The parties (including AMRN) agree this was incorrect? I thought it wasn’t verifiable that any subjects had TG over 500
Thx again Pharma. I agree (processing and encapsulation)
Thx Pharma!
I’m just spitballing here, but wouldn’t there have to be some scientific proof that any generic is really the equivalent of V? From what I understand, V is difficult to manufacture (ester form?) and the encapsulation method prevents oxidation, etc.
I’m a little over my head here. Maybe someone smarter could weigh in? Or, maybe I’m full of shit?
Anyone heard from Hamoa lately?
TTE - I like the way you think!!
Kiwi
1) if settled before trial I’d guess a pop of 2 or more
2) if it goes to trial I think the pps may struggle as the shorts have fun
a) if AMRN wins trial then same as #1
b) I can’t bear to think of what happens if we lose
Kiwi - I’d probably crap my pants first, then sell
KIWI - If you’re gonna scold me then I think you should scold the whole class:)
Truer words never been spoken.